Research graph
References from Quetiapine modestly improves sleep and breathing but impairs next-day performance in people with obstructive sleep apnea and difficulty maintaining sleep: a randomized controlled trial. Local targets link to admitted publications; unresolved targets remain external evidence.
Quetiapine is not a sleeping pill
10.4045/tidsskr.19.0205 · 2019 · External reference
How common is off-label prescription of quetiapine?
2018 · External reference
Dispensed prescriptions for quetiapine and other second-generation antipsychotics in Canada from 2005 to 2012: a descriptive study
10.9778/cmajo.20140009 · 2014 · External reference
Low doses of mirtazapine or quetiapine for transient insomnia: a randomised, double-blind, cross-over, placebo-controlled trial
10.1177/0269881116681399 · 2017 · External reference
Unresolved reference
2022 · External reference
Unresolved reference
2025 · External reference
Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis
10.1016/s2213-2600(19)30198-5 · 2019 · External reference
Epidemiology of insomnia: what we know and what we still need to learn
10.1053/smrv.2002.0186 · 2002 · External reference
Prevalence and associations of co-morbid insomnia and sleep apnoea in an Australian population-based sample
10.1016/j.sleep.2021.03.023 · 2021 · External reference
Gender differences in the prevalence of and trends in sleep patterns and prescription medications for insomnia among US adults, 2005 to 2018
10.1016/j.sleh.2022.07.004 · 2022 · External reference
Treatment preferences and help seeking experiences of Australian adults with insomnia
10.1080/00050067.2025.2534388 · 2026 · External reference
Time trends in the family physician management of insomnia: the Australian experience (2000–2015)
10.5664/jcsm.6616 · 2017 · External reference
Increased prevalence of sleep-disordered breathing in adults
10.1093/aje/kws342 · 2013 · External reference
Effects of the antipsychotic quetiapine on sleep and breathing: a review of clinical findings and potential mechanisms
10.1111/jsr.14051 · 2024 · External reference
Defining phenotypic causes of obstructive sleep apnea: identification of novel therapeutic targets
10.1164/rccm.201303-0448oc · 2013 · External reference
Novel avenues to approach non-CPAP therapy and implement comprehensive obstructive sleep apnoea care
10.1183/13993003.01788-2021 · 2022 · External reference
Phenotypic approaches to obstructive sleep apnoea—new pathways for targeted therapy
10.1016/j.smrv.2016.12.003 · 2018 · External reference
The norepinephrine reuptake inhibitor reboxetine alone reduces obstructive sleep apnea severity: a double blind, placebo controlled, randomized, cross-over trial
10.5664/jcsm.10256 · 2023 · External reference
Unresolved reference
2022 · External reference
Obstructive sleep apnea endotypes and their postoperative relevance
10.1097/aia.0000000000000357 · 2022 · External reference
Eszopiclone increases the respiratory arousal threshold and lowers the apnoea/hypopnoea index in obstructive sleep apnoea patients with a low arousal threshold
10.1042/cs20100588 · 2011 · External reference
Trazodone increases the respiratory arousal threshold in patients with obstructive sleep apnea and a low arousal threshold
10.5665/sleep.3596 · 2014 · External reference
Trazodone effects on obstructive sleep apnea and non-REM arousal threshold
10.1513/annalsats.201408-399oc · 2015 · External reference
Effects of hypnotics on obstructive sleep apnea endotypes and severity: novel insights into pathophysiology and treatment
10.1016/j.smrv.2021.101492 · 2021 · External reference
The noradrenergic agent reboxetine plus the antimuscarinic hyoscine butylbromide reduces sleep apnoea severity: a double-blind, placebo-controlled, randomised crossover trial
10.1113/jp281912 · 2021 · External reference
Impact of cold and flu medication on obstructive sleep apnoea and its underlying traits: a pilot randomized controlled trial
10.1111/resp.14009 · 2021 · External reference
Antipsychotic off-label use in the 21st century: an enduring public health concern
10.1080/19585969.2025.2449833 · 2025 · External reference
On-and off-label utilisation of antipsychotics in Australia (2000–2021): retrospective analysis of two medication datasets
10.1177/00048674231210209 · 2024 · External reference
Off-label prescribing of antipsychotics in adults, children and elderly individuals: a systematic review of recent prescription trends
10.2174/1381612821666150619092903 · 2015 · External reference
Safety of low-dose quetiapine for insomnia in older adults
10.1007/s40266-024-01170-5 · 2025 · External reference
Unresolved reference
2022 · External reference
Validation of the Karolinska Sleepiness Scale against performance and EEG variables
10.1016/j.clinph.2006.03.011 · 2006 · External reference
The utility of the AusEd driving simulator in the clinical assessment of driver fatigue
10.3758/bf03193039 · 2007 · External reference
Phenotyping pharyngeal pathophysiology using polysomnography in patients with obstructive sleep apnea
10.1164/rccm.201707-1435oc · 2018 · External reference
Polysomnographic endotyping to select patients with obstructive sleep apnea for oral appliances
10.1513/annalsats.201903-190oc · 2019 · External reference
Quantifying the arousal threshold using polysomnography in obstructive sleep apnea
10.1093/sleep/zsx183 · 2018 · External reference
Clinical predictors of the respiratory arousal threshold in patients with obstructive sleep apnea
10.1164/rccm.201404-0718oc · 2014 · External reference
Hypnotics on obstructive sleep apnea severity and endotypes: a systematic review and meta-analysis
10.1164/rccm.202403-0501oc · 2024 · External reference
Quetiapine for primary insomnia: consider the risks
10.3949/ccjm.88a.20031 · 2021 · External reference
Drugs for insomnia beyond benzodiazepines: pharmacology, clinical applications, and discovery
10.1124/pr.117.014381 · 2018 · External reference
A brief review of quetiapine
10.1176/appi.ajp-rj.2022.180207 · 2022 · External reference
Comparison of D2 dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects
10.1017/s1461145711000514 · 2011 · External reference
A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy
10.1001/archpsyc.57.6.553 · 2000 · External reference
Systematic review of driving simulator validation studies
10.1016/j.ssci.2019.04.004 · 2019 · External reference
Comparison of driving errors between on-the-road and simulated driving assessment: a validation study
10.1080/15389580902894989 · 2009 · External reference
Effects of alcohol and sleep restriction on simulated driving performance in untreated patients with obstructive sleep apnea
10.7326/0003-4819-151-7-200910060-00005 · 2009 · External reference
Driving simulator performance remains impaired in patients with severe OSA after CPAP treatment
10.5664/jcsm.1062 · 2011 · External reference
Individual variability and predictors of driving simulator impairment in patients with obstructive sleep apnea
10.5664/jcsm.3792 · 2014 · External reference
Patients’ and caregivers’ experiences of driving with chronic breathlessness before and after regular low-dose sustained-release morphine: a qualitative study
10.1177/0269216320929549 · 2020 · External reference
Morbidity and mortality from road injuries: results from the Global Burden of Disease Study 2017
10.1136/injuryprev-2019-043302 · 2020 · External reference
Unresolved reference
2025 · External reference
Medications and risk of motor vehicle collision responsibility in British Columbia, Canada: a population-based case-control study
10.1016/s2468-2667(21)00027-x · 2021 · External reference
Insomnia is associated with road accidents. Further evidence from a study on truck drivers
10.1371/journal.pone.0187256 · 2017 · External reference
Impaired driving performance associated with effect of time duration in patients with primary insomnia
10.5665/sleep.4012 · 2014 · External reference
Predictors of driving risk in patients with obstructive sleep apnea syndrome treated by continuous positive airway pressure: a French multicenter prospective cohort
10.1093/sleep/zsae211 · 2024 · External reference
The effect of experimentally induced sleep fragmentation and estradiol suppression on neurobehavioral performance and subjective sleepiness in premenopausal women
10.1093/sleep/zsae130 · 2024 · External reference
Effect of quetiapine, from low to high dose, on weight and metabolic traits: results from a prospective cohort study
10.1055/a-1525-2820 · 2021 · External reference
Safety of low doses of quetiapine when used for insomnia
10.1345/aph.1q697 · 2012 · External reference
Use of low-dose quetiapine increases the risk of major adverse cardiovascular events: results from a nationwide active comparator-controlled cohort study
10.1002/wps.21010 · 2022 · External reference
Clinical polysomnographic methods for estimating pharyngeal collapsibility in obstructive sleep apnea
10.1093/sleep/zsac050 · 2022 · External reference
